Oxygenta Pharmaceutical Share Price Today | Stock Price & Oxygenta Pharmaceutical Share Screener
As of October 5, 2026, the live Oxygenta Pharmaceutical share price (BSE: OXYGENTAPH) is ₹46.96, down 2.17% from the previous close, with shares trading between ₹46.05 and ₹48.78 in today's trading session, and a 52-week range of ₹44.61–₹67.88. Check OXYGENTAPH 52-week high low for the annual price range and momentum. Use the Oxygenta Pharmaceutical stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Oxygenta Pharmaceutical opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹113 and net income of ₹-17, with EBITDA of ₹-17, an operating margin of -24.0% and a profit margin of -15.0%.
Oxygenta Pharmaceutical Share Price Chart
Track the current stock price of Oxygenta Pharmaceutical with an interactive chart. Analyse OXYGENTAPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Oxygenta Pharmaceutical stock quote in one place.
The quote of ₹46.96 sits between the 52-week low of ₹44.61 and the 52-week high of ₹67.88, and the latest session moved -2.17% from the previous close.
Oxygenta Pharmaceutical Company Profile - Fundamental Screener
Screen Oxygenta Pharmaceutical company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for OXYGENTAPH shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE102E01018.
Company Details
Classification
Identifiers and Leadership
Oxygenta Pharmaceutical Balance Sheet Screener
Screen OXYGENTAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹83 against total liabilities of ₹83, up from ₹63 in 2024.
Latest statistics put total assets at ₹83 and shareholder funds at ₹-25.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 |
| Current Assets | 31 | 24 | 25 | 10 | 16 | 7 | 9 | 4 | 6 | 5 |
| Fixed Assets | 40 | 29 | 28 | 20 | 16 | 11 | 12 | 12 | 12 | 13 |
Liabilities |
||||||||||
| Total Liabilities | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 |
| Current Liabilities | 23 | 50 | 68 | 58 | 54 | 43 | 38 | 29 | 29 | 21 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | -25 | -20 | -46 | -35 | -38 | -41 | -35 | -32 | -27 | -22 |
| Share Capital | 37 | 34 | 14 | 14 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | -62 | -54 | -60 | -49 | -48 | -51 | -45 | -42 | -38 | -32 |
Oxygenta Pharmaceutical Income Statement Screener - Profit & Revenue Analysis
Screen Oxygenta Pharmaceutical income statement and profit fundamentals. Analyze OXYGENTAPH quarterly results. Oxygenta Pharmaceutical reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹113 and net profit was ₹-17, equal to earnings per unit of ₹-2.50, at an operating margin of -24%.
In that period expenses were ₹130, interest cost ₹4 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹111 and net profit of ₹-10.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 113 | 111 | 40 | 31 | 61 | 52 | 14 | 21 | 14 | 9 | 12 | 6 |
| Expenses | 130 | 119 | 49 | 38 | 59 | 48 | 22 | 23 | 17 | 13 | 17 | 10 |
Operating Costs and Margins | ||||||||||||
| EBITDA | -17 | -9 | -10 | -7 | 2 | 4 | -8 | -2 | -3 | -4 | -4 | -4 |
| Operating Profit % | -24.00% | -9.00% | -24.00% | -23.00% | 2.00% | 7.00% | -57.00% | -10.00% | -31.00% | -59.00% | -34.00% | -66.00% |
| Depreciation | 2 | 1 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Interest | 4 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | -23 | -12 | -14 | -11 | -1 | 3 | -6 | -4 | -5 | -6 | -6 | -7 |
| Tax | 0 | -2 | -10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Profit | -17 | -10 | -4 | -12 | -1 | 3 | -6 | -3 | -5 | -6 | -6 | -6 |
| EPS | -2.50 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | -5.99 |
Oxygenta Pharmaceutical Cash Flow Screener - Liquidity Fundamentals
Screen OXYGENTAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹3.
Over the same period, investing activities used ₹11 and financing activities provided ₹9.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 3 | -13 | -2 | -2 | -2 | -3 | -8 | 1 | 1 | 1 |
| Investing Activities | -11 | -4 | -10 | -5 | -7 | -1 | -1 | 0 | -1 | -2 |
Financing and Net Cash | ||||||||||
| Financing Activities | 9 | 17 | 11 | 6 | 9 | 3 | 8 | -1 | 0 | 1 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Oxygenta Pharmaceutical Shareholding Pattern Screener
See Oxygenta Pharmaceutical shareholding pattern with promoter, FII, and DII holdings. Check Oxygenta Pharmaceutical promoter holding and ownership changes for OXYGENTAPH on TickJournal, and see how institutional stock price moves affect the market.
In 2025-Mar, promoters held 51.12%, foreign institutions 0.00%, domestic institutions 0.03% and the public 43.93%, spread across 10,030 shareholders.
The shareholder count was 10,030 in 2025-Mar, compared with 10,094 in 2025-Jun.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 51.12% | 57.92% | 57.95% | 29.73% | 33.69% | 53.28% | 51.12% | 8.99% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.07% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.93% | 36.65% | 36.55% | 53.31% | 50.30% | 41.81% | 43.93% | 52.89% |
| Other Holding | 4.93% | 5.41% | 5.47% | 16.94% | 15.98% | 4.89% | 4.93% | 38.05% |
| Shareholder Count | 10,030 | 10,094 | 10,179 | 10,102 | 9,975 | 10,154 | 10,111 | 8,995 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Oxygenta Pharmaceutical. Oxygenta Pharmaceutical dividend yield can be compared with peers and other stocks in the market.
Oxygenta Pharmaceutical Stock Index Membership - Nifty & Sensex
See which indices include Oxygenta Pharmaceutical stock. Check OXYGENTAPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Oxygenta Pharmaceutical Market Events Screener - Corporate Actions
Get Oxygenta Pharmaceutical corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Oxygenta Pharmaceutical stock events that may affect OXYGENTAPH share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 7, 2025, with a record date of November 7, 2025.
It is followed by Annual General Meeting dated September 19, 2025 and Quarterly Result Announcement dated August 14, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 4.96% |
| 2025-09-19 | 2025-09-19 | Annual General Meeting | NA | -11.86% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -8.16% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.57% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.62% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -9.59% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 41.46% |
| 2024-05-09 | 2024-05-09 | Extraordinary General Meeting | NA | 8.38% |
| 2021-12-06 | 2021-12-06 | Change Of Name | NA | 0.00% |
Oxygenta Pharmaceutical Competitors Screener - Peer Stocks Comparison
Screen OXYGENTAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Oxygenta Pharmaceutical Company Announcements - News & Reports Screener
Screen OXYGENTAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 30, 2026.
The next most recent announcements are dated September 30, 2026 and December 11, 2025.
| Date | Update | Actions |
|---|---|---|
| 2026-09-30 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-30 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-11 | Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) To Stock Exchanges Regarding Approval Of The Shareholders For Reclassification Of Person(S) Forming Part Of Th | - |
| 2025-12-11 | Minutes Of The Resolutions Passed By Way Of Postal Ballot | - |
| 2025-12-11 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2025-12-11 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-11 | Intimation Of Calendar Of Events For The Postal Ballot Process Under Regulations 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2025-11-11 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-11-07 | Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025 | - |
| 2025-11-07 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.11.2025 | - |
| 2025-11-03 | Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025. 2. Limited Review Report For The Quarter Ended September 30 2025. 3. Any Other Business With The Permission Of The Chair. | - |
| 2025-10-22 | Disclosure Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2025-10-18 | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | - |
| 2025-10-18 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-10-16 | Announcement Under Regulation 30 | - |
| 2025-09-26 | Closure of Trading Window | - |
| 2025-09-19 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-09-19 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹46.96, within a 52-week range of ₹44.61 to ₹67.88. The P/E ratio is 15.00 and the P/B ratio is -5.54, with earnings per unit of ₹-2.69. Market capitalisation stands at ₹203.44 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.